William Blair Downgrades Actinium (ATNM) to Market Perform, 'Due to Changing Paradigm, Regulatory Risks, Commercial Headwinds for Lead Asset Iomab-B'
Tweet Send to a Friend
(Updated - February 21, 2023 7:20 AM EST)
William Blair analyst Andy Hsieh downgraded Actinium Pharma (NYSE: ATNM) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
William Blair analyst Andy Hsieh downgraded Actinium Pharma (NYSE: ATNM) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
